This is a working overview of Stability, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-14 and is reviewed periodically as new material appears.
In the NAD+ salvage pathway, the enzyme NAMPT converts nicotinamide and a phosphate-donor molecule into NMN. A second enzyme, NMNAT, then converts NMN into NAD+. Nicotinamide riboside can also enter this route after being converted to NMN by nicotinamide riboside kinases. Because NMN sits at a junction between precursor uptake and NAD+ formation, its cellular concentration is tightly linked to enzyme activity and tissue type. NAD+ participates in redox reactions, signaling, and DNA repair, and its levels decline with age in some animal models, though human evidence remains more limited and context-dependent.
Research interest in NMN increased after animal studies reported that oral or injected NMN can raise NAD+ levels in some tissues. How NMN is absorbed and distributed in humans is not fully established. Some evidence suggests extracellular NMN may be dephosphorylated to nicotinamide riboside before cellular uptake, while other studies propose specific transport routes. Direct human data on these mechanisms remain limited. Regulatory status also varies: in some countries NMN is treated as a dietary supplement, while elsewhere it is restricted or requires approval, and these differences affect labeling, sale, and research.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide found in the cells of many organisms. Its structure consists of a nicotinamide group linked to a ribose sugar that carries a phosphate group. NMN is an intermediate in the biosynthesis of nicotinamide adenine dinucleotide, or NAD+, a coenzyme involved in many metabolic reactions. The abbreviation usually refers to the beta anomer, though related forms can exist. In scientific literature, NMN is distinct from nicotinamide riboside, another NAD+ precursor.
Solid NMN is generally handled as a moisture-sensitive compound. Dry material stored desiccated at low temperature, protected from light, tends to remain stable for extended periods. Aqueous solutions are less stable and can undergo hydrolysis, especially at elevated temperature or alkaline pH. The anomeric form also matters: beta-NMN is the naturally occurring form, while alpha-NMN can appear as a synthetic impurity. Purity and storage conditions therefore influence both analytical results and experimental reproducibility.
Identity and purity are usually assessed with complementary methods. Nuclear magnetic resonance spectroscopy can confirm the molecular structure and distinguish anomeric forms. High-performance liquid chromatography with ultraviolet detection or mass spectrometry is common for assay and related-substance testing. Mass spectrometry also supports trace quantification in biological samples, often with isotope-labeled internal standards. Because NMN lacks a strong chromophore, some ultraviolet methods require careful wavelength selection or derivatization, and laboratories may validate each approach for its intended matrix.
Commercial NMN is produced through enzymatic or chemical routes, and the resulting material can vary in purity, counterion, and residual solvent content. Buyers typically rely on certificates of analysis, but independent verification through third-party laboratories provides stronger assurance. Regulatory treatment differs by country; in the United States, NMN has been subject to shifting guidance about its status as a dietary supplement, while other markets permit sales under local rules. No universal pharmacopeial monograph exists for NMN, so specifications often come from suppliers, research protocols, or regional requirements.
| Property | Value | Notes |
|---|---|---|
| Chemical name | Nicotinamide mononucleotide | Common name; beta form often denoted beta-NMN |
| Chemical formula | C11H15N2O8P | As free acid; salt forms differ |
| Molar mass | 334.22 g/mol | Calculated for the free acid |
| CAS Registry Number | 1094-61-7 | For beta-nicotinamide mononucleotide |
| Biochemical role | NAD+ intermediate | Participates in the salvage biosynthesis pathway |
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide base with a ribose sugar and a phosphate group. Within cells, NMN sits on the biosynthetic route that recycles nicotinamide back into nicotinamide adenine dinucleotide, or NAD+. Because NAD+ participates in redox reactions and signaling, enzymes that produce and consume it influence many metabolic processes. The compound is therefore best described as an intermediate rather than a final signaling molecule.
In the canonical salvage pathway, nicotinamide phosphoribosyltransferase, known as NAMPT, transfers a phosphoribosyl group to nicotinamide and releases NMN. A second enzyme, NMN adenylyltransferase, then attaches an adenylyl group to NMN to form NAD+. Alternative routes exist, including a pathway that uses nicotinamide riboside and its phosphorylated forms. The relative contribution of extracellular NMN to intracellular NAD+ pools remains an area of active investigation, and the roles of specific transporters and enzymes are not completely defined.
NMN is present in small amounts in various foods, including certain vegetables, fruits, and milk, though dietary quantities are generally low. Laboratory research often uses synthetic or enzymatically produced NMN. The compound has drawn interest because NAD+ levels decline with age in some tissues and because restoring NAD+ may affect metabolism in animal models. Whether oral NMN produces meaningful NAD+ increases in humans and whether such changes translate into health benefits are not fully established.
Analytical laboratories identify and quantify NMN using several complementary techniques. High-performance liquid chromatography with ultraviolet detection is widely used for purity and assay work. Liquid chromatography coupled to mass spectrometry provides greater sensitivity and is common for biological matrices. Nuclear magnetic resonance spectroscopy supports structural confirmation and can distinguish related nucleotides. Accurate measurement depends on reference standards, validated methods, and careful sample preparation, especially because NMN can convert to related compounds under some conditions.
Regulatory treatment of NMN varies by jurisdiction and has changed over time. Some countries allow it in dietary supplements, while others treat it as a novel food ingredient requiring safety review. In the United States, the Food and Drug Administration has questioned whether NMN can be lawfully marketed as a dietary supplement because of drug preclusion provisions. Sports organizations have separate rules, and NMN is not currently on the World Anti-Doping Agency prohibited list. These differences create uncertainty for manufacturers, retailers, and researchers seeking consistent legal pathways.
Nicotinamide mononucleotide, usually shortened to NMN, is a naturally occurring nucleotide. Its structure consists of a nicotinamide base linked to a ribose sugar that carries a phosphate group. In cells, NMN serves as an intermediate in the salvage pathway that produces nicotinamide adenine dinucleotide, or NAD+. Because NAD+ participates in many oxidation-reduction reactions, NMN sits near central metabolic processes. The compound is not a drug in most jurisdictions and is discussed mainly in biochemistry and nutrition research.
The term NMN commonly refers to the beta isomer, in which the nicotinamide group is attached to the ribose through a beta-glycosidic bond. Commercial material may be supplied as the free acid or as a salt, such as a sodium salt, which affects molecular weight and water solubility. Related compounds include nicotinamide riboside and NAD+ itself, but these are distinct molecules with different formulas and cellular handling. Laboratory research often uses the beta form because it matches the naturally occurring configuration found in biological systems.
Small amounts of NMN occur in some foods, including certain vegetables, fruits, and animal products, though the quantities are generally low and variable. Human cells also synthesize NMN internally from nicotinamide and other precursors. Research interest increased after studies examined whether raising NAD+ levels affects metabolism and aging-related pathways in animals. Evidence in humans remains limited and mixed for many outcomes, and questions about effective absorption, tissue delivery, and long-term effects are still open. Regulatory status differs by country, with some markets treating NMN as a supplement ingredient and others restricting its sale.
The period during which a trial is attempting to identify and enroll participants. Recruitment activities can include advertising and other ways of soliciting interest from possible participants (NLM) Recruitment status
=== Music === The third season includes several original songs, written by the series composer Christopher Lennertz, with two of them being "Rock My Kiss" and "You've Got a License to Drive (Me Crazy)". Both songs are featured respectively in the first ("Payback") and second episodes ("The Only Man in the Sky"), which were performed by Miles Gaston Villanueva. The music video for the latter was released on September 10, 2022. Lennertz delved further for the creation of these new songs by request of Kripke, creating a fictional in-universe musical boyband named Super-Sweet for which Villanueva's character Supersonic is the leader. Wanting to capture the essence of an authentic boyband during the decades of 1990s and 2000s, musical bands like NSYNC, Backstreet Boys, New Kids on the Block and Boyz II Men were researched by Lennertz, intending to understand the vibes that he needed for his tunes and develop a story for the group in the series in order to achieve and develop the fictional band's sound. Given all the profanity the series had, Lennertz needed to ensure that none of the songs had any swearing since "no boyband would ever do that", while also intending to trick the people to make them believe that they already heard and knew about those songs. Lennertz also wrote other two songs being "America's Son" and "Chimps Don't Cry". Both songs are featured in the second episode ("The Only Man in the Sky"), which were performed by Laurie Holden. The latter song got a music video for which it was released on June 17, 2022.
=== Recent history === An IRA bomb exploded near the railway station in March 1997, damaging signalling equipment. The original IRA message was confusing and led to the evacuation of the Wilmslow police station to the local leisure centre not far from the explosion. Nobody was hurt. In the general election of the same year, the parliamentary constituency of Tatton, in which Wilmslow falls, made headlines as part of the "sleaze" accusations levelled against the then Conservative Government. Tatton MP, Neil Hamilton, was accused of accepting cash for tabling Parliamentary questions; he was defeated subsequently in the election by independent candidate Martin Bell. Bell was supported in his door to door canvassing for votes by David Soul and served a single term as MP.
Sources: en.wikipedia.org
Affair of Half a Lifetime (simplified Chinese: 半生缘; traditional Chinese: 半生緣; pinyin: Bànshēng Yuán) is a 2003 Taiwanese drama-romance TV series based on the 1948 novel of the same name by Chinese author Eileen Chang. It stars Ruby Lin, Patrick Tam, Jiang Qinqin, and Li Liqun. The series had the most simultaneous broadcasts on Chinese cable/satellite TVs in 2004. It was filmed in Shanghai and Taiwan.
1996: Insulin lispro, which was originally manufactured by Eli Lilly and Company, is granted approval. 2000: Insulin aspart, which was created by Novo Nordisk, is approved. 2000: Insulin glargine, which was developed by Sanofi-Aventis, is approved. 2004: Insulin glulisine, also developed by Sanofi-Aventis, is approved. 2005: Insulin detemir, which was formulated by Novo Nordisk, gets approval. 2015: Insulin degludec, created by Novo Nordisk, is approved. 2020: Insulin lispro-aabc, a faster insulin lispro formulation created by Eli Lilly and Company, is approved. 2021: Insulin glargine-yfgn, the first approved insulin biosimilar, which is produced by Viatris, is approved. 2021: Insulin glargine-aglr, a biosimilar produced by Eli Lilly and Company, is granted approval. 2024: Insulin icodec, the newest commercially available analogue by Novo Nordisk, gets approval. 2025: Insulin aspart-szjj, the first short-acting biosimilar, created by Viatris, is approved.
== Industry == In 2020, the American market for dietary supplements was valued at $140.3 billion, with the economic impact in the United States for 2016 estimated at $122 billion, including employment wages and taxes. A 2020 analysis projected that the global market for vitamins and dietary supplement products would reach $196.6 billion by 2028, where the growth in market size is largely attributed to recent technological advancements in product manufacturing, increased demand for products advertised as healthy, increased product availability, and population aging.
Sources: en.wikipedia.org
Nicotinamide mononucleotide is a nucleotide intermediate in the biosynthesis of NAD+. It consists of nicotinamide attached to a ribose phosphate unit. NMN occurs naturally in cells and is present at low levels in some foods.
NMN is a direct precursor in the NAD+ salvage pathway. Enzymes called NMNAT convert NMN into NAD+, a coenzyme used in metabolism and cell signaling. Raising NMN may increase NAD+ in some experimental settings, but the effect depends on tissue and organism.
No. Nicotinamide riboside is a related compound that lacks the phosphate group present in NMN. Cells can convert nicotinamide riboside into NMN, and both compounds feed into NAD+ production through overlapping routes.
Purity is commonly measured by high-performance liquid chromatography with ultraviolet or mass spectrometric detection. Nuclear magnetic resonance can confirm identity and anomeric composition. Water content and residual solvents may be tested separately.